|Bid||117.25 x 100|
|Ask||117.60 x 200|
|Day's Range||115.50 - 117.95|
|52 Week Range||94.42 - 127.64|
|PE Ratio (TTM)||44.05|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Barclays initiated coverage of Zymeworks Inc (NYSE: ZYME ) with an Overweight rating and price target of $20. The company released first-quarter earnings last week, reporting ($1.13) EPS on the quarter ...
Celgene stock dipped to a four-month low Monday after ozanimod failed to show a disability benefit over interferon in multiple sclerosis patients.